Patent 8362215 was granted and assigned to Trellis Bioscience on January, 2013 by the United States Patent and Trademark Office.
Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.